ESMO 2023 pancreatic cancer guidelines signal stepwise progress  

作　　者：Christoph Springfeld Peter Bailey Markus W.Büchler John P.Neoptolemos 

机构地区：[1]Medical Oncology,National Center for Tumor Diseases,Heidelberg University Hospital,Heidelberg,Germany [2]Division of Applied Bioinformatics,The German Cancer Research Center(DKFZ),Heidelberg,Germany [3]Department of General,Visceral and Transplantation Surgery,Heidelberg University Hospital,Heidelberg,Germany

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第2期362-365,共4页肝胆外科与营养（英文）

摘　　要：Pancreatic ductal adenocarcinoma(PDAC)is still a devastating disease,and for those who treat PDAC patients it sometimes seems that there is little to no relevant progress.The excellent new ESMO clinical practice guideline by Conroy et al.(1)points to important advances in pancreatic cancer therapy that were made since the previous edition from 2015(2).According to the American Cancer Society the overall five-year survival for all stages of PDAC has improved from 5%some 30 years ago to 13%in the present day.The major thrust lies in greatly improved outcomes for resectable pancreatic cancer with 5-year survival increasing from 5-10%at the beginning of this period to 30-50%due to technical improvements in surgery along with combination adjuvant chemotherapy.

关 键 词：Resectable BORDERLINE ADJUVANT NEOADJUVANT persister cells 

分 类 号：R735.9[医药卫生—肿瘤]